PE20130199A1 - Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores - Google Patents

Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores

Info

Publication number
PE20130199A1
PE20130199A1 PE2012002019A PE2012002019A PE20130199A1 PE 20130199 A1 PE20130199 A1 PE 20130199A1 PE 2012002019 A PE2012002019 A PE 2012002019A PE 2012002019 A PE2012002019 A PE 2012002019A PE 20130199 A1 PE20130199 A1 PE 20130199A1
Authority
PE
Peru
Prior art keywords
robo1
protein
fusion protein
tumor treatment
refers
Prior art date
Application number
PE2012002019A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Tarik Dabdoubi
Frederique Dol-Gleizes
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20130199A1 publication Critical patent/PE20130199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA PROTEINA RECOMBINANTE Robo-Fc QUE COMPRENDE: A) EL DOMINIO EXTRACELULAR DE LA ISOFORMA b DE LA PROTEINA Robo1 QUE COMPRENDE LOS DOMINIOS INMUNOGLOBULINA Ig1 Y Ig2, Y PRESENTA 80% DE IDENTIDAD CON LA SECUENCIA SEQ ID Nº 2; B) UN CONECTOR; Y C) UN DOMINIO Fc DE LA INMUNOGLOBULINA G4 HUMANA QUE CONTIENE LAS MUTACIONES S241P Y L248E, Y ESTA AUSENTE LA LISINA DE LA POSICION C-TERMINAL PARA AUMENTAR LA ESTABILIDAD DE LA PROTEINA, ELIMINAR LA ACTIVIDAD EFECTORA RESIDUAL DEL DOMINIO Fc O AUMENTAR LA HOMOGENEIDAD DURANTE SU PRODUCCION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DONDE SE SOBREEXPRESA UNA PROTEINA SLIT TAL COMO CANCER
PE2012002019A 2010-04-14 2011-04-08 Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores PE20130199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
PE20130199A1 true PE20130199A1 (es) 2013-03-09

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002019A PE20130199A1 (es) 2010-04-14 2011-04-08 Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores

Country Status (27)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
PH (1) PH12012502044A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023098A1 (fr) 1993-04-05 1994-10-13 Daikin Industries, Ltd. Fibre de polytetrafluoroethylene, materiau cotonneux contenant ladite fibre, et procede de production dudit materiau
KR20130132880A (ko) * 2010-12-23 2013-12-05 사노피 간암의 치료에 사용하기 위한 ｒｏｂｏ１－ｆｃ 융합 단백질
HRP20190116T1 (hr) 2012-01-05 2019-03-08 Boston Medical Center Corporation Slit-robo signaliziranje, namijenjeno dijagnosticiranju i liječenju bubrežne bolesti
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
KR20200016292A (ko) 2017-06-02 2020-02-14 화이자 인코포레이티드 재조합 robo2 단백질, 조성물, 방법 및 그의 용도
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
US12139531B2 (en) 2019-04-23 2024-11-12 The Regents Of The University Of California Compositions and methods useful in promoting milk production
TW202511284A (zh) * 2023-09-14 2025-03-16 大陸商北京拓界生物醫藥科技有限公司 包含robo結構域的蛋白及其醫藥用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
WO1999020764A1 (en) * 1997-10-20 1999-04-29 The Regents Of The University Of California Robo: a family of polypeptides and nucleic acids involved in nerve guidance
CA2324284A1 (en) 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
US7939497B2 (en) 2002-03-08 2011-05-10 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
ATE528397T1 (de) * 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
CN102391358B (zh) * 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP3067368A1 (en) * 2007-04-27 2016-09-14 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
EP2195023B1 (en) 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
US9493529B2 (en) 2016-11-15
CA2796303A1 (fr) 2011-10-20
ECSP12012230A (es) 2012-11-30
US20130039912A1 (en) 2013-02-14
EA201291044A1 (ru) 2013-04-30
EP2558489A1 (fr) 2013-02-20
WO2011128561A1 (fr) 2011-10-20
MX338981B (es) 2016-05-06
GT201200275A (es) 2014-01-24
CL2012002879A1 (es) 2013-03-22
CN102884076A (zh) 2013-01-16
UY33334A (es) 2011-12-01
DOP2012000265A (es) 2013-02-28
AU2011239839A1 (en) 2012-11-08
CR20120508A (es) 2012-11-01
MA34221B1 (fr) 2013-05-02
FR2958936A1 (fr) 2011-10-21
AR080891A1 (es) 2012-05-16
TW201142024A (en) 2011-12-01
BR112012026020A2 (pt) 2016-06-28
MX2012011822A (es) 2012-11-12
NI201200155A (es) 2013-02-05
PH12012502044A1 (en) 2017-07-26
IL222382A0 (en) 2012-12-31
SG184529A1 (en) 2012-11-29
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
IL222382A (en) 2016-06-30
TN2012000473A1 (fr) 2014-01-30
AU2011239839B2 (en) 2015-08-20
KR20130059329A (ko) 2013-06-05

Similar Documents

Publication Publication Date Title
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
CY1126074T1 (el) Περιοχες gla ως παραγοντες στοχευσης
ECSP17073650A (es) Proteínas de fusión
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
MX2016015868A (es) Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina.
CU20140034A7 (es) Proteínas de fusión para tratar trastornos metabólicos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
EA201690469A1 (ru) Слитый белок
GT201700224A (es) Proteína de unión a rgma y su uso
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
CY1124280T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.

Legal Events

Date Code Title Description
FD Application declared void or lapsed